|
New Products
- Drospirenone (Slinda), derived from spironolactone, is a progestogen-only pill. In therapeutic dosages, drospirenone also possesses antiandrogenic and mild antimineralocorticoid properties. It has no estrogenic, glucocorticoid and antiglucocorticoid activity. This gives drospirenone a pharmacological profile closely resembling the natural hormone progesterone. Slinda is indicated for contraception. It should not be used in the presence of active venous thromboembolic disorder; presence or history of severe hepatic disease as long as liver function values have not returned to normal; severe renal insufficiency or acute renal failure; known or suspected sex-steroid sensitive malignancies; undiagnosed vaginal bleeding; or known or suspected pregnancy. Should any of the conditions appear for the first time during its use, Slinda should be discontinued immediately. Slinda tablets contain drospirenone 4 mg and are available in a pack size of 28 tablets (24 active, 4 placebo tablets) or 84 tablets (72 active, 12 placebo tablets).
- Risdiplam (Evrysdi) is a survival of motor neuron 2 (SMN2) pre-mRNA splicing modifier designed to treat spinal muscular atrophy (SMA) caused by mutations in chromosome 5q that lead to SMN protein deficiency. Functional SMN protein deficiency is the pathophysiological mechanism of all SMA types. Evrysdi corrects the splicing of SMN2 to shift the balance from exon 7 exclusion to exon 7 inclusion into the mRNA transcript leading to an increased production in functional and stable SMN protein. Thus, Evrysdi treats SMA by increasing and sustaining functional SMN protein levels. Evrysdi is indicated for the treatment of 5q SMA in patients aged 2 months and older. Evrysdi powder for oral solution contains risdiplam 0.75 mg/mL after reconstitution and is available in pack size of one 80 mL bottle with two 6 mL and two 12 mL reusable oral syringes and a bottle adapter.
|
|
|
New Presentation
- Infliximab (rmc) (Remsima) is now available as a solution for subcutaneous injection containing infliximab (rmc) 120 mg/mL in a pack size of one 1 mL prefilled syringe (with automatic needle guard) or prefilled pen. Subcutaneous use of Remsima is recommended for adults only.
|
|
|
New Indications
- Ixekizumab (rch) (Taltz) is now indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or MRI evidence, who have responded inadequately to, or are intolerant to, nonsteroidal anti-inflammatory drugs.
|
|
|
New Contraindications
- Clindamycin (phosphate)/Tretinoin (Acnatac) is now contraindicated in patients who have a personal or familial history of skin cancer.
- Flucytosine (Ancotil) is now contraindicated in patients with known complete dihydropyrimidine dehydrogenase deficiency.
|
|
|
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.
|
|
|
|
|
|
|
|
|
